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V-raf-1 murine leukemia viral oncogene homolog 1 (Raf-1) is a key
activator of the ERK pathway and is a target for cross-regulation of
this pathway by the cAMP signaling system. The cAMP-activated
protein kinase, PKA, inhibits Raf-1 by phosphorylation on S259. Here,
we show that the cAMP-degrading phosphodiesterase-8A (PDE8A)
associates with Raf-1 to protect it from inhibitory phosphorylation
by PKA, thereby enhancing Raf-1’s ability to stimulate ERK signaling.
PDE8A binds to Raf-1 with high (picomolar) afﬁnity. Mapping of the
interaction domain on PDE8A using peptide array technology iden-
tiﬁed amino acids 454–465 as the main binding site, which could be
disrupted by mutation. A cell-permeable peptide corresponding to
this region disrupted the PDE8A/Raf-1 interaction in cells, thereby
reducing ERK activation and the cellular response to EGF.Overexpres-
sion of a catalytically inactive PDE8A in cells displayed a dominant
negative phenotype on ERK activation. These effects were recapitu-
lated at the organism level in genetically modiﬁed (PDE8A−/−) mice.
Similarly, PDE8 deletion in Drosophila melanogaster reduced basal
ERK activation and sensitized ﬂies to stress-induced death. We pro-
pose that PDE8A is a physiological regulator of Raf-1 signaling in
some cells.
V-raf-1 murine leukemia viral oncogene homolog 1 (Raf-1) isat the apex of the mitogen activated protein kinase (MEK)–
ERK pathway, which controls many fundamental biological pro-
cesses including cell proliferation, survival, and transformation. In
this pathway Raf-1 phosphorylates and activates MEK, which in
turn phosphorylates and activates ERK. ERK has more than 150
known substrates whichmediatemany of the pleiotropic functions
of this pathway (1). Raf-1 regulation is complex and still is in-
sufﬁciently understood. Critical events are the dephosphorylation
of an inhibitory site, S259, which allows Raf-1 binding to activated
rat sarcoma viral oncogene (Ras) and is a prerequisite for further
activation (2, 3). S259 is a target for phosphorylation by PKA
(4, 5) and is part of a complex system of crosstalk between the
cAMP and the ERK pathways.
The cAMP system is the ﬁrst signal-transduction system iden-
tiﬁed as mediating the intracellular biochemical effects of hor-
mones (6), and PKA has been recognized as a main effector of
cAMP (7). The intimate connections between the cAMP andERK
pathways were ﬁrst revealed when PKAwas shown to inhibit Raf-1
by direct phosphorylation (8–13). The exact mechanism of in-
hibition has remained unclear. Several phosphorylation sites in
Raf-1 were invoked in the inhibitory action [e.g., S43, which could
interfere with Raf-1 binding to Ras (13); S621, which can inhibit
Raf-1 kinase activity directly (10); S233, which mediates inhibitory
14-3-3 binding; and S259, which blocks Raf-1 translocation to the
plasma membrane and Ras binding (4, 5)]. Although the mecha-
nistic function of most of these phosphorylation sites has remained
controversial (14), S259 has emerged clearly as major inhibitory
site whose dephosphorylation is part of the physiological activa-
tion process of Raf-1 and is mandatory for Raf-1 activation to
ensue (2, 3). In addition, several other mechanisms of crosstalk
have been discovered, including the regulation of Ras family
proteins by cAMP-sensitive exchange factors and the phosphory-
lation of phosphodiesterases (PDEs) by ERK (15, 16).
Cyclic nucleotide PDEs terminate cAMP signaling by hydro-
lyzing cAMP, with this enzyme class featuring a large number of
genes and isoforms that are regulated by differential expression,
alternative splicing, and distinct modes of subcellular compart-
mentalization (17). Critically, studies on the cAMP-speciﬁc phos-
hodiesterase-4 (PDE4) family of enzymes have shown that the
targeting of distinct PDE isoforms to speciﬁc signaling complexes
and localities in cells underpins compartmentalized cAMP sig-
naling (18, 19) and allows the development of spatially discrete
gradients of cAMP that control spatially restricted subpopulations
of the cAMP effectors PKA and exchange protein directly acti-
vated by cAMP (EPAC) (20).
Recently, there has been a surge of interest in the cAMP-
speciﬁc phoshodiesterase-8 (PDE8) family of enzymes. PDE8s
are expressed widely in human tissue (21) with functions in tes-
tosterone production (22), lymphocyte adhesion (23), chemo-
taxis (24), and excitation–contraction coupling in ventricular
myocytes (25). PDE8 isoforms exhibit an extremely high afﬁnity
for cAMP (26), and this unique feature has led to the suggestion
that PDE8 enzymes may have a very important cellular role in
protecting any associated protein from ﬂuctuations in basal
cAMP concentrations. Compartmentalization of cAMP-speciﬁc
PDEs with PKA substrates has been recognized as a mechanism
that not only protects the substrates from inappropriate PKA
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phosphorylation under basal conditions but also ensures speciﬁcity
of action when a single receptor type is activated to produce a
second messenger, such as cAMP, that is common to many other
receptors (19). Here, we report that at least part of the PDE8A
in the cell can bind tightly to Raf-1, regulate Raf-1 phosphory-
lation on S259, and, in so doing, regulate the cross-talk node
whereby cAMP exerts an inhibitory effect on Raf-1 signaling,
retarding subsequent ERK phosphorylation and activation.
Results
PDE8A Localizes with Raf-1 Immunoprecipitates. To look for binding
partners for Raf-1, immunoprecipitates of Raf-1 from HEK293
cells were digested with trypsin and subjected to peptide map
ﬁngerprinting analysis using a mass spectrometer. PDE8A was
identiﬁed as a 95-kDa Raf-1–associated protein with seven
PDE8A peptides identiﬁed in the spectra (Fig. S1). To validate
the interaction between Raf-1 and PDE8A, immunoprecipitates
of Raf-1 were tested for PDE activity and were found to contain
PDE activity that was inhibited by dipyridimole, an effective and
partially selective PDE8 inhibitor (Fig. 1A). Because these data
strongly suggested that PDE8A and Raf-1 can exist in a complex,
Raf-1 immunoprecipitates were screened for associated PDE8A
using Western blotting (Fig. 1B). With this technique, a PDE8A-
speciﬁc antibody detected a protein of the correct weight that was
associated with Raf-1. To verify further the association of Raf-1
and PDE8A, we undertook overexpression studies in which epi-
tope-tagged constructs of Raf-1 (Myc tag) and PDE8A (Flag tag)
were coexpressed in HEK293 cells, and immunoprecipitates of
both tags were probed for bothMyc–Raf-1 and Flag-PDE8A (Fig.
1C). Control immunoprecipitates used antibodies against an un-
related tag (vesicular stomatitis virus). Raf-1 coimmunoprecipi-
tated with PDE8A, and vice versa. The PDE8A–Raf-1 association
was not caused by nonspeciﬁc interaction, because the control
immunoprecipitates showed no coimmunoprecipitating species.
To determine whether the association of PDE8A and Raf-1
depended on cAMP concentrations within cells, the immuno-
precipitations were repeated following treatment with forskolin
alone or with forskolin in conjunction with either a nonspeciﬁc
PDE inhibitor, 3-isobutyl-1-methylxanthine (IBMX), or a PDE8-
selective inhibitor (Fig. 1 D and E). None of these treatments
inﬂuenced the amount of PDE8A that copuriﬁed with Raf-1, or
vice versa, suggesting that a preformed complex of PDE8 and
Raf-1 exists in HEK293 cells.
Fig. 1. PDE8 and Raf-1 form a constitutively assembled complex. (A) Immunoprecipitations (IP) of Raf-1 or control IgG from HeLa cells were analyzed for
associated PDE activity. Raf-1 Immunoprecipitations contained PDE activity that was inhibited by 100 μM dipyridimole (DiP). (B) Immunoprecipitates of en-
dogenous Raf-1 from HeLA cells brings down PDE8A1. (C) Tagged constructs of Raf-1 (Myc tag) and PDE8A (Flag tag) were coexpressed in HEK293, and
immunoprecipitates of both tags were probed for both Myc-Raf-1 and Flag- PDE8A. IB, immunoblot. (D and E) Immunoprecipitates with PDE8A Flag antibody
(D) and with Raf-1 Myc antibody (E). Immunoprecipitates as in A were repeated following treatment with forskolin alone (100 μM, 10 min) or with forskolin
(100 μM, 10 min) in conjunction with either a nonselective PDE inhibitor (IBMX, 100 μM, 10-min pretreatment) or a PDE8-selective inhibitor (dipyridimole,
100 μM, 10-min pretreatment).
2 of 10 | www.pnas.org/cgi/doi/10.1073/pnas.1303004110 Brown et al.
PDE8 Activity Regulates Raf-1 Phosphorylation at Ser259. Because
the biochemical data presented above suggested an interaction
between Raf-1 and PDE8A, we assessed whether PDE8 activity
could inﬂuence the amount of basal phosphorylation of Raf-1 at
S259 in HEK293 cells using Licor Odyssey technology, a quanti-
tative Western blotting method (Fig. 2). PDE8A overexpression
signiﬁcantly reduced phosphorylation at S259. Conversely, ex-
pression of a catalytically inactive form of PDE8A (D/N-PDE8A)
resulted in a dominant-negative phenotype, a concept we had
developed previously in studies of PDE4 isoforms (27). Over-
expression of this construct signiﬁcantly augmented phosphory-
lation at S259 on Raf-1, presumably by displacing the endogenous
PDE8A from its binding site on Raf-1 (Fig. 2). Treatment with the
partially selective PDE8 inhibitor dipyridimole also signiﬁcantly
increased S259 phosphorylation of Raf-1. Additionally, increases
in Raf-1 S259 phosphorylation that ensued upon treatment of
cells with the adenylyl cyclase activator forskolin were either
inhibited by PDE8A overexpression or augmented by D/N-
PDE8A overexpression. Because PDE8A activity makes up
a small percentage (<5%) of the total PDE activity in these cells
but has such a profound effect on basal phospho-S259 Raf-1
levels (Fig. 2, bars 6, 7, and 8), but on not the global PKA phos-
phorylation of PKA substrates (Fig. S2), we decided to ascertain
whether PDE8A and Raf-1 interact directly.
PDE8A Interacts Directly with Raf-1. To determine whether the
interaction was direct, we incubated puriﬁed PDE8–myelin basic
protein (MBP) with either GST–Raf-1 or GST alone and per-
formed a GST-pulldown experiment (Fig. 3A). PDE8 copuriﬁed
with GST–Raf-1 but not with GST alone, suggesting that the
interaction between PDE8 and Raf-1 is direct. Finally, we de-
termined the afﬁnity of the interaction of PDE8A and Raf-1 via
surface plasmon resonance (SPR) analysis (Fig. 3B). GST–Raf-1
was coupled to the chip using an anti-GST antibody (Materials
and Methods) and was probed with MBP–PDE8A (Fig. 3B). The
afﬁnity of interaction was extremely high, being in the mid to
low picomolar range (Kd <61 pM). However, because the af-
ﬁnity of the proteins was so high, less than 5% dissociation
occurred during an extended assay time of 4 h, precluding an
accurate determination of the rate of dissociation (Fig. 3C).
Therefore, the upper limit of kd has been used for calculating the
equilibrium dissociation constant Kd. We additionally tested
the effects of dipyridimole on the formation and stability of the
complex, but this inhibitor did not alter the interaction between
Raf-1 and PDE8A (Fig. 3D), indicating that inhibitor binding
to the active site does not affect the interaction between PDE8
and Raf-1. Control chips that had reference surfaces consisting
of immobilized GST alone showed no interaction with MBP–
PDE8A.
Mapping the Site of Interaction for Raf-1 on PDE8A. Peptide array
technology has been successfully used by us (28–30) and others
(31, 32) to map the interfaces between interacting proteins. This
information can be used to design cell-permeable disrupting
peptides and to inform mutagenesis strategies aimed at creating
null-binding mutants (33, 34). To map the sites of interaction
between Raf-1 and PDE8A, we synthesized a peptide array of
human PDE8A consisting of 25mer peptides overlapping by ﬁve
amino acids that encompassed the entire PDE8A sequence (Fig.
4).We then probed this array with either GST alone orGST–Raf-1
and detected areas of interaction by blotting for the GST tag. A
robust interaction of GST–Raf-1 (but not GST alone) was iden-
tiﬁed on peptide spots 89, 90, and 91, which correspond to amino
acids 442–476 within the PDE8A sequence (Fig. 4A). A detailed
alanine scan of this region, in which successive residues were
replaced by alanine residues, showed that the major residues in-
volved in the interaction were D443, R454, R455, E460, Y461,
and L463 (Fig. 4B). Further proof that the PDE8A sequence 454–
461 (RRLSGNEY) was required for the association of Raf-1 was
obtained using truncation analysis (Fig. 4C) of immobilized
peptides. Stepwise C-terminal truncation revealed that this se-
quence was the minimum required to maintain Raf-1 binding.
To conﬁrm the importance of PDE8A residues E460 and Y461
for the association of Raf-1, we mutated both residues to alanine
and repeated the immunoprecipitation experiment from Fig. 1.
Mutation of these residues attenuated but did not fully ablate the
interaction of the proteins (Fig. 5A), suggesting that other resi-
dues in the 454–461 (RRLSGNEY) minimum binding region also
were important for the formation of the Raf-1–PDE8A complex.
Because a double alanine substitution of R454A:R455A was
found to abolish Raf-1 interaction on peptide array (Fig. 4B), we
combined this double mutation with the E460A:Y461Amutation.
This quadruple mutant (R454A:R455:A:E460A:Y461A) further
reduced binding to 15.3% ± 3.8% of the wild type (mean ± SE of
n = 3; P < 0.05) (Fig. 5B), underlining the importance of this
region in conferring interaction between PDE8A and Raf-1.
Peptide Disruption of the Raf-1–PDE8A Complex. Previous work
from our laboratory has shown that cell-permeable analogs of
25mer peptides identiﬁed in this manner often can be used to
disrupt signaling complexes within cells, thereby affecting speciﬁc
functional outputs such as phosphorylation of the β2-adrenergic
receptor by PKA (33) and the phosphorylation of β-arrestin by
ERK MAPK (29). In this study, we used the Raf-1–docking se-
quence from PDE8A, encompassing residues R454–T465, to
manufacture a stearylated, cell-permeable disruptor peptide. As
a control, we also synthesized a scrambled version of the steary-
lated peptide that had the same net weight and charge (Peptide
Cont). Both peptides had a C-terminal stearate group that allows
transport across the cell membrane (29). The disruptor peptide,
but not the control peptide, attenuated the association between
PDE8A and Raf-1 when measured in immunoprecipitation ex-
periments from cellular lysates (Fig. 5C andD). The disruption of
the complex induced by the peptide (33.8± 18.1%; n=3, P< 0.05)
Fig. 2. PDE8 activity regulates phosphorylation of Raf-1 at serine 259. (A)
HEK293 cells were transfected with Flag-PDE8A1 (lanes 2, 4, and 5) or dom-
inant-negative PDE8A1 (lanes 7 and 8) and/or were treated with dipyr-
idamole (DiP, lanes 5 and 6) or forskolin (FSK, lanes 3, 4, 5, and 8). The level of
phospho-Raf-1 (S259) (pRaf-1) relative to total Raf-1 was monitored using
a Licor Odyssey system, in which the band density measured using a pRaf-1
phospho-ser 259 antibody (B, second panel from the top) was divided by the
total Raf-1 density (B, Top). The second panel from the bottom depicts the
merged image of the upper two panels. Example data are from Licor Odyssey.
(Bottom) Western blot showing relative expression of PDE8A construct. n = 4,
with the exception of the dominant-negative PDE8A + forskolin sample, in
which n = 3. *P < 0.05; **P < 0.01 relative to the control (Con) samples.
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was not as marked as that of the quadruple mutant R454A:R455:
A:E460A:Y461A (15.3 ± 3.8%; n= 3, P < 0.05) (Fig. 5B), but this
difference could be caused by cell permeability and afﬁnity issues:
Although we treated cells with a relatively high concentration of
peptide (10 μM), we have no way of accurately measuring the
amount that reaches the cell cytoplasm. We did, however, detect
a 43% decrease in association of the endogenous proteins in
HEK293 cells following treatment with disruptor peptide (Fig.
S3B). It should be noted that, because the afﬁnity of the in-
teraction is extremely high (Fig. 3), we may not expect to achieve
a complete disruption of a preformed complex between Raf-1 and
PDE8A using a peptide. However, the disruptor peptide mark-
edly decreased basal phospho-ERK in HEK293 cells (Fig. 6A)
and increased basal phospho-Raf-1 levels (Fig. S3A) and could
markedly attenuate phospho-ERK levels induced by short-term
(0–3 min) EGF treatment (Fig. 6B).
In agreement with these results, overexpression of a catalyti-
cally inactive form of PDE8A exerted a dominant-negative ac-
tion by signiﬁcantly reducing resting phospho-ERK levels in
HEK293 cells. In this case, however, the EGF-induced phospho-
ERK response remained unaltered (Fig. 6C).
To determine whether the control of resting phospho-ERK
levels by PDE8A activity occurs at the organismal level, we studied
the phospho-ERK levels in wild-type ﬂy strains that are known to
exhibit canonical ERK signaling (35) and in a PDE8-knockout
(PDE8−/−) Drosophila mutant (Fig. 6D). We also determined
phospho-ERK levels in the Leydig cells of an established PDE8A
knockout (PDE8A−/−) mouse model and compared them with
the levels observed in matched wild-type controls (Fig. 6E). In
agreement with the changes in basal phospho-ERK seen HEK293
cells, resting phospho-ERK levels were reduced markedly in
both the PDE8-knockout ﬂy and the PDE8A-knockout mouse.
Phospho-ERK levels induced by 3-min EGF treatment also were
reduced signiﬁcantly in Leydig cells from PDE8A-knockout
mice compared with the same cells isolated from wild-type mice
(Fig. 6E).
Disruption of the PDE8A–Raf-1 Complex Alters Functional Responses
to EGF and Stress Signals. Growth factor-induced morphological
changes can be quantiﬁed in cells by measuring impedance (36,
37), which provides a real-time, noninvasive analysis suitable for
measuring the kinetics of short- and long-term cellular respon-
ses. Changes in cellular impedance triggered by agents such as
EGF and insulin have been shown to correlate with those mea-
sured by conventional means [e.g., autophosphorylation of the
EGF receptor as measured by ELISA (36)], and impedance now
is commonly used for assessing morphological changes such as
membrane rufﬂing or formation of lamellipodia in a quantita-
Fig. 3. PDE8A binds to Raf-1 with high afﬁnity. (A) Puriﬁed PDE8–MBP was mixed with puriﬁed GST–Raf-1 or GST alone, and a GST-pulldown experiment was
undertaken (Materials and Methods). (B) GST–Raf-1 was coupled to a Biacore chip using an anti-GST antibody and was probed with increasing concentrations
of MBP–PDE8A. (C) MBP–PDE8A (100 nM) was used to probe a GST–Raf-1 chip. The injection was done with or without inclusion of 50 μM dipyridimole. A
control injection of 50 μM dipyridimole was undertaken also. (D) Dissociation of the GST–Raf-1–PDE8–MBP complex was observed over 250 min.
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tive fashion. We used xCELLigence technology (Roche) to mea-
sure the impedance of cell cultures in which we perturbed the
PDE8A–Raf-1 interaction.
First, to ensure a maximal signal, we constructed a dose–
response curve in HeLa cells to evaluate the effect of increasing
EGF concentration on cell impedance (the “cell index”) (Fig.
7A). Maximal response occurred at 50 ng/mL EGF, a value
reported previously by others as producing maximal impedance
(36). Next we tested the effect of the disruptor peptide and
control peptide on the maximal cell index produced in HeLa
cells after EGF treatment (Fig. 7B). The disruptor peptide
clearly attenuated the maximal increase in cell index, and this
effect was mimicked by overexpression of the catalytically in-
active (dominant-negative) PDE8A construct in HeLa cells (Fig.
7C). These data suggest that integrity of the PDE8A–Raf-1
complex is crucial for maximal EGF signaling leading to mor-
phological changes. These results agree well with the premise
that PDE8A activity is integral for the regulation of Raf-1–
dependent ERK signaling in HEK293 cells, and primary mouse
Leydig cells (Fig. 6).
Using impedance-based analysis, we also monitored the re-
sponse of cells to stress, because loss of oxidative stress tolerance
has been linked to the amplitude of the ERK signaling response
(38). Treatment of HEK293 cells with either hydrogen peroxide
or staurosporine reduced the cell viability to a level that was
markedly enhanced by the transfection of a dominant-negative
PDE8A construct (Fig. 7 D and E). Because hydrogen peroxide
and staurosporine also can induce cell death, we assessed
whether PDE8 plays a role in survival signaling. For this purpose
we used Drosophila melanogaster as a model system. Indeed, we
found that the disruption of the endogenous PDE8 gene in-
creased the sensitivity of ﬂies to treatment with either hydrogen
peroxide or paraquat. The survival rate of ﬂies fed with 1%
hydrogen peroxide was signiﬁcantly reduced in male PDE8-
Fig. 4. Mapping of the Raf-1 binding site on PDE8A. (A) A peptide array of human PDE8A consisting of 25mer peptides overlapping by ﬁve amino acids that
encompassed the entire PDE8A sequence was overlaid with either GST or GST–Raf-1. Positive interactions were detected with peptides 89, 90, and 91 that
correspond to a sequence encompassing amino acids 442–476 of PDE8A1. (B) Peptide arrays in which successive residues (442–466) of the sequence within
peptide 89 were replaced by alanine were overlaid with either GST or GST–Raf-1. (C) Stepwise C-terminal truncation of sequences within peptide 89 revealed
the “core” binding motif that associates with Raf-1.
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deﬁcient ﬂies as compared with the wild-type CantonS and
Exilesis parents (Fig. 8A) and in female ﬂies against both controls
(Fig. 8B). The survival rate of male (Fig. 8C) and female (Fig. 8D)
ﬂies fed with 20 mM paraquat was signiﬁcantly reduced in
PDE8-deﬁcient ﬂies compared with both control strains. Thus,
PDE8 function enhances survival at both the cellular and the
organism levels.
Discussion
Regulation of Raf activity is of pivotal important to the control
of cell growth, survival, and differentiation through the ERK
signaling pathway (1). One important point of control is the in-
hibitory phosphorylation of Raf-1 by PKA. However, to date the
factors that inﬂuence this key regulatory event have been ob-
scure. Here we identify a means of controlling this inhibitory
process through sequestration of the cAMP-hydrolyzing PDE8A
enzyme with Raf-1 itself. The importance of individual PDE
families is becoming more appreciated, especially in the light of
the bewildering complexity of PDE isoform expression and the
often very speciﬁc biological effects of isoform-selective PDE
inhibitors (18). The cAMP effector PKA also can bind to Raf-1,
but, in contrast to PDE8A, the binding of PKA to Raf-1 is dis-
rupted by cAMP agonists (4). Thus, PDE8A may function as a
local, tonic antagonist of cAMP signaling, setting the threshold
that needs to be overcome for Raf-1 activation. This view is
consistent with our results, because we show that displacement of
endogenous PDE8A by a catalytically inactive species generates
a dominant-negative phenotype (Figs. 2 and 7). Additionally, the
effects of a cell-permeable PDE8A disruptor peptide and genetic
silencing of PDE8A to reduce the basal local PDE8A activity
and subsequent increase in Raf-1 activation (Fig. 6) also add
weight to this proposal.
This identiﬁcation of only the second binding partner identi-
ﬁed for PDE8A [PDE8A also associates with IκB (39)] and of
a PDE associated with Raf-1 strongly suggests that spatial reg-
ulation of Raf-1 can occur through sequestration of PDE8A.
This ﬁnding may open opportunities to manipulate Raf-1 acti-
vation by pharmacological agents that modulate PDE8A and to
evaluate changes in this system in disease states. Raf-1 activation
is increasingly in the limelight as a promising drug target. Al-
though Raf-1 is rarely mutated in cancer (40), B-Raf frequently
is mutated in melanoma (41), and the B-Raf–selective inhibitor
PLX4720 has shown impressive clinical efﬁcacy in the treatment
of B-Raf–mutated melanomas (42). However, in melanomas
with Ras mutations, these inhibitors were ineffective and even
may cause tumor progression. The reason seems to be a para-
doxical activation of ERK caused by the promotion of Raf-1–
B-Raf heterodimerization, which is stimulated by mutant Ras
and Raf inhibitors (43, 44). The B-Raf–Raf-1 heterodimer has
kinase activity>30-fold higher than that of the respective homo-
dimers or monomers, even when one of the two Raf kinases is
inactivated (45). Thus, despite being pharmacologically inhibited,
B-Raf can recruit Raf-1 for signaling and efﬁcient activation of the
ERK pathway. In this context, PDE8A inhibitors should be ben-
eﬁcial and possibly synergistic with Raf inhibitors; as is shown
here, PDE8A inhibition can impede the activation of Raf-1. This
hypothesis is supported by recent ﬁndings that melanocytes use
B-Raf to activate ERK, because Raf-1 activity is suppressed by
high cAMP levels (46). However, in response to Ras mutations
occurring during melanoma development, cells switch to use Raf-1
to activate the ERK pathway (46). This switch is promoted by
mutant Ras stimulating a negative-feedback phosphorylation of
B-Raf by ERK and an elevation of PDE4 activity. This shift de-
inhibits Raf-1 and enables Raf-1–mediated oncogenic signaling.
In fact, inhibiting Raf-1 by activating cAMP signaling blocks
proliferation and induces apoptosis of Ras-mutated melanoma
cells (47). Thus, PDE8A-selective inhibitors may become im-
portant pharmacological agents to counteract oncogenic Raf
signaling.
Materials and Methods
Cell Culture and Transfection. HEK 293 and HeLa cells were cultured in DMEM
supplemented with 10% FCS, 1% penicillin-streptomycin, and 1% L-gluta-
mine (all from Sigma) at 37 °C in humidiﬁed air with 5% CO2 [all concen-
trations are (vol/vol)]. Transfections were performed using Polyfect (Qiagen)
according to the manufacturer’s instructions. Primary mouse Leydig cells
were prepared and cultured from wild-type and PDE8A−/−mice as previously
described (22). All animal usage and procedures were approved by the In-
stitutional Animal Care and Use Committee of the University of Washington
in accordance with the National Institutes of Health.
Mammalian Cell-Expression Constructs. Human Flag-tagged PDE8A1 in the
pCMV-2 plasmid was a gift from Kenji Omori (Tanabe Seiyaku Co. Ltd., Japan).
The pEF-myc-Raf-1 construct was provided by Chris Marshall (Institute of
Cancer Research, London), and pGEX-KG-Raf-1 was described previously (10).
For single transfections, 8 μg of DNA was used per 100-mm plate; for dual
transfections, 4 μg of each construct was transfected.
Chemicals and Antibodies. Forskolin, dipyridamole, and IBMX (Sigma) were
dissolved in DMSO and were added to cell media at a concentration of <0.1%
DMSO. EGF, staurosporine, and hydrogen peroxide were all obtained from
Sigma. Antibodies against the myc tag (1:2,000), phospho-ERK (1:1,000), ERK
(1:1,000), and phospho-Raf-1 (pS259; 1:1,000) were obtained from Cell Sig-
naling. Raf-1 (1:2,000) and PDE8A (1:2,000) antibodies were purchased from
BD Biosciences and Scottish Biomedical, respectively. HRP-conjugated Flag
antibody (1:2,000) was from Sigma, and GST antibody (1:2,000) was obtained
from Santa Cruz.
PDE Assay and Cellular Transfection of PDE8A1. PDE activity was measured
using a radioactive cAMP hydrolysis assay that has been described previously
(27). [8-3H] Adenosine cyclic-3′, 5′-monophosphate was from Amersham
Biosciences, and cyclic-3′, 5′-monophosphate was obtained from Sigma. The
substrate concentration used for PDE assays was 150 nM. Raf-1 immuno-
precipitations were done from 400 μg of cellular lysate.
MS Analysis of Raf-1 Immunoprecipitates. Growing cells (1 × 107) were lysed
in PBS supplementedwith 1%Triton X-100 and protease inhibitors (Complete
protease inhibitor mixture tablets; Roche) and phosphatase inhibitors
(PhosSTOP tablets; Roche). Lysates were cleared by centrifugation (20,000 × g
for 10 min), and the supernatant was immunoprecipitated with Raf-1
Fig. 5. Dissociation of the PDE8A–Raf-1 complex by site-directed muta-
genesis and peptide disruption. (A) Mutation of PDE8A1 residues 460E461Y to
alanines attenuated the interaction between PDE8A and Raf-1 as measured
by coimmunoprecipitation. (B) Quadruple mutation of PDE8A1 residues
454R455R460E461Y to alanine further attenuated the interaction between
PDE8A and Raf-1 as measured by coimmunoprecipitation. (C) A cell-per-
meable peptide corresponding to amino acids R454–T465 attenuated the
association between PDE8A and Raf-1 when measured in immunoprecipi-
tation experiments from cellular lysates. A randomly scrambled version of
this peptide (Scrambled peptide control, cont.) did not affect the interaction
between PDE8A and Raf-1. (D) Quantiﬁcation of the effectiveness of the
PDE8–Raf-1 disruptor peptide in dissociating the complex.
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antibodies for 2 h at 4 °C. Immunoprecipitates were washed three times in
lysis buffer and separated on 7.5% SDS gels. Gels were stained with colloidal
Coomassie stain (0.1% Coomassie R-250, 50% methanol, 5% acetic acid, and
45% Milli-Q water) and were destained in destaining solution (40% metha-
nol, 10% acetic acid, and 50%Milli-Q water) until the background was clear.
Bands were cut out from the gel and chopped into ∼1-mm2 pieces. The gel
pieces were washed with distilled water for 15 min, followed by two washes
with 100mMNH4HCO3/CH3CN (50:50 vol/vol) for 15min. Then gel pieces were
crushed with a Teﬂon pestle, dehydrated in CH3CN, and dried in a SpeedVac
(Thermo Fisher Scientiﬁc) for 5 min. Gel pieces were incubated with 12.5 mg/
mL of modiﬁed porcine trypsin (Promega) in 20 mM NH4HCO3/0.1% nOctyl-
Glucoside at 30 °C overnight. Then an equal volume of CH3CN was added to
the digest, followed by incubation at 30 °C for 30 min on a shaking platform.
The digest supernatant was removed and dried down in a SpeedVac. The
digest was resuspended in 10 mL of 50% CH3CN in 0.1% triﬂuoric acid and
was analyzed on a Voyager-DE Pro MALDI-TOF (Applied Biosystems) by
peptide mass ﬁngerprinting using 2,5-dihydroxy benzoic acid as matrix.
Western Blotting. Cells were lysed in 3T3 lysis buffer [1% Triton X-100, 50 mM
Hepes (pH 7.2), 10 mM EDTA, and 100 mM NaH2PO4·2H2O] supplemented
with a protease inhibitors tablet (Roche). Detergent-insoluble proteins were
removed by centrifugation at 10,000 × g for 10 min. Aliquots of the soluble
fraction were resolved by SDS/PAGE using the NuPAGE system (Invitrogen).
Proteins were transferred to nitrocellulose membrane (Protran; Whatman
GmbH) for 1 h at 25V using NuPAGE Transfer buffer. The membranes were
blocked in 5% nonfat dry milk (Marvel, Premier International Foods)/Tris-
buffered saline supplemented with 0.1% Tween-20 (TBS-T) for at least 1 h
before primary antibodies were added in 1% Marvel/TBS-T and incubated at
4 °C overnight. The membranes were washed three times for 10 min in TBS-
T. Peroxidase- or Alexa Fluor-conjugated secondary antibodies were added
in 1% Marvel/TBST and incubated for 1 h at room temperature. Membranes
were washed as before, and bound primary antibodies were detected by in-
cubation with appropriate secondary antibodies using either ECL or the Licor
Odyssey scanner for ﬂuorescence detection. Densitometry on ﬁlm was per-
formed using Quantity One software (BioRad Laboratories). Fluorescence
intensity was measured using the Odyssey software (Licor). For ECL de-
tection, the mouse (Amersham) and rabbit (Sigma) secondary antibodies
were used at a 1:5,000 concentration. The Odyssey secondary antibodies
Alexa-Fluor 680 and Alexa-Fluor 800 were diluted 1:10,000.
Immunoprecipitation Experiments. Myc-Raf-1 and Flag-PDE8A1 were immu-
noprecipitated from 400 –1,000 μg of total protein lysate made up to a total
volume of 400 μL with 3T3 lysis buffer using 50 μL Myc (Sigma) or Flag
(Invitrogen) antibodies coupled to agarose beads. The immunoprecipitates
were incubated for at least 2 h or overnight at 4 °C with constant agitation
before the beads were washed at least three times with 3T3 lysis buffer. For
endogenous immunoprecipitates, 10 μg PDE8A antibody was incubated with
1,000 μg HeLa cell lysate overnight at 4 °C with constant agitation. Washed
protein-G beads (Amersham) (75 uL) were added for 1–2 h before the beads
were pelleted and washed as above.
Fig. 6. Manipulation of the PDE8–Raf-1 complex alters the strength of basal and EGF-stimulated phospho-ERK signals. (A) Treatment of HEK293 cells with
the disruptor peptide (Dis) signiﬁcantly down-regulated basal phospho-ERK Map kinase levels compared with cells treated with the scrambled peptide control
(Con). n = 3. (B) Pretreatment of HEK293 cells with disruptor peptide, but not scrambled control, signiﬁcantly attenuated phospho-ERK levels induced by
short-term (0- to 3-min) EGF treatment. (C) Overexpression of D/N PDE8 signiﬁcantly reduced resting phospho-ERK levels in HEK293 cells. (D) Basal phospho-
ERK levels are decreased signiﬁcantly in the PDE8 knockout Drosophila compared with two control lines. (E) Basal phospho-ERK levels, and those induced by
short-term (0- to 3-min) EGF treatment are attenuated in primary mouse Leydig cells derived from the PDE8A−/−mouse as compared with those derived from
a wild-type mouse. n = 3. *P = 0.037, one-way ANOVA.
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Peptide Arrays. Peptide libraries were produced by automatic SPOT synthesis
(48). They were synthesized on continuous cellulose membrane supports on
Whatman 50 cellulose membranes using 9-ﬂuorenylmethyloxycarbonyl
chemistry with the AutoSpot-Robot ASS 222 (Intavis Bioanalytical Instru-
ments). The interactions of spotted peptides with GST and GST–Raf-1 were
determined by overlaying the membranes with 10 μg/mL recombinant
protein. Bound proteins were detected with GST antibody (Santa Cruz),
and detection was performed with a secondary anti-rabbit antibody cou-
pled with HRP (1:2,500 dilution; Dianova) and ECL detection.
Disruptor Peptides.All peptides were purchased fromGenScript and dissolved
in DMSO. The disruptor peptide (R454–T465) RRLSGNEYVLST was designed
based on the results of the peptide array. The scrambled control peptide
SYTVRLLGERNS sequence was created by randomly scrambling the disruptor
peptide sequence, ensuring no vital residues were in the same position. To
make them cell permeable, peptides were synthesized with a stearic acid
group [CH3(CH2)16COOH] attached to the C terminus. Peptides were added
to cells at a ﬁnal concentration of 10 μM for 4 h before cells were harvested.
Site-Directed Mutagenesis. Site-directed mutagenesis was performed using
the QuickChange kit (Stratagene). All primers were obtained from Thermo
Scientiﬁc, and sequencing was performed by the DNA Sequencing Service at
the University of Dundee, Dundee, Scotland. The following primers were used
to create the required mutations:
R454A/R455A mutant:
Forward primer: 5′-CTTAATGTCTGATGGTTTGGCGGCCCTATCAGGGAATG-
AATATGTTC-3′
Reverse primer: 5′-GAACATATTCATTCCCTGATAGGGCCGCCAAACCATCA-
GACATTAAG-3′
E460A/Y461A mutant:
Forward primer: 5′-CTATCAGGGGAATGCAGCTGTTCTTTCAACAAAAAAC-
ACTCAAATGG-3′
Reverse primer: 5′-CCATTTGAGTGTTTTTTGTTGAAAGAACAGCTGCATTCC-
CTGATAG-3′
Both R454A/R455A and E461A/Y461A mutants were veriﬁed by se-
quencing using the F3 primer (SPR Experiments).
R454A/R455A/E460A/Y461A mutants:
Forward primer: 5′-gggcttaatgtctgatggtttggcagcactatcagggaatgcagctgtt-3′
Reverse primer: 5′-aacagctgcattccctgatagtgctgccaaaccatcagacattaagccc-3′
PDE8A1 dominant negative D726A mutant:
Forward primer:; 5′-gctgattaaatgtgctgctgtgtccaatccctgcc-3′
Reverse primer: 5′-ggcagggattggacacagcagcacatttaatcagc-3′
The D726A mutant was veriﬁed by sequencing using the CMV24 primer
5′-GTGCCCACCAGCCTTGTCCTAATA-3′.
HEK293 cells overexpressing wild-type Flag-PDE8A1, D/N PDE8A1 and
mock transfected cells were blotted for immunoreactivity and normalized to
equal expression levels. The catalytic activity of D/N PDE8A1 versus wild-type
PDE8A1 was measured by PDE assay as described elsewhere (27).
Fig. 7. Disruption of the PDE8–Raf-1 complex alters functional responses to EGF and stress signals. (A) The EGF-induced change of cell shape in HeLa cells
measured by real-time impedance measurement is dose dependent. (B) The PDE8–Raf-1 disruptor peptide but not the scrambled control (cont) attenuates the
cell-shape change induced by EGF in HeLa cells. (C) Overexpression of D/N PDE8A signiﬁcantly reduced cell-shape changes in HeLa cells induced by EGF. (D)
Cell death induced in HEK293 cells by treatment with 500 nM staurosporine is enhanced when cells are transfected with D/N PDE8A. (E) Cell death induced in
HEK293 cells by treatment with 10 μM hydrogen peroxide is enhanced when cells are transfected with D/N PDE8. *P < 0.05, **P < 0.01.
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In Vitro Binding Assay. Equimolar amounts (2 μM) of puriﬁed recombinant
GST (negative control) and GST–Raf-1 and PDE8A1 protein (Scottish Bio-
medical) were mixed in binding buffer [50 mM Tris·HCl (pH7.5), 100 mM
NaCl, 2m MMgCl2, 1 mM DTT, 0.5% (vol/vol) Triton X-100, 0.5% (wt/vol) BSA,
and protease inhibitors] and were incubated for 1 h at 4 °C. Then 30 μL of
GST beads were washed and equilibrated in binding buffer, added to the
protein mixture, and incubated as before for 1 h. Beads were sedimented by
centrifugation at 10,000 × g for 1 min, and washed three times. Proteins
associated with the beads were eluted by boiling in sample buffer and were
analyzed by Western blotting.
SPR Experiments. SPR analysis was performed using a Biacore 2000 instrument
(GE Healthcare). Anti-GST antibody (GST Capture Kit, GE Healthcare) was
immobilized to a level of 15,000 response units (RU) onto CM5 sensor chips
(GE Healthcare) according to the manufacturer’s instructions. The fusion
protein GST–Raf-1 (100 nM) was reversibly captured to a level of 165–200
RU. As control surface, an anti-GST surface captured with GST (1 μg/mL) was
prepared. The interaction study was performed in HBS buffer [20 mM Hepes
(pH 7.4), 150 mM NaCl, and 0.01% surfactant Tween20] at 30 °C. Kinetic
constants were determined by injecting a series of dilutions of MBP–PDE8A1
(900–3.5 nM) over GST–Raf-1 on the capture surfaces at a ﬂow rate of 30 μL/min.
The association was monitored for 5 min, and dissociation of the complex
was followed for 60 min. Because less than 5% of the complex dissociates
within 60 min, the dissociation time of the highest concentration (900 nM)
was prolonged to 480 min and used for quantiﬁcation of the dissociation
rate constant (kd). After each interaction event, the antibody surface was
regenerated using two pulses of 10 mM glycine (pH 1.7). Data were evalu-
ated using the software BIAevaluation 4.1 (GE Healthcare) and Graphpad
Prism 5.04 (GraphPad Software Inc.). Kinetic rate constants (ka and kd) were
determined by simultaneously ﬁtting experimental data to rate equations
derived from a Langmuir 1:1 binding model. Because the kd can be de-
termined accurately only if at least 5% of bound material dissociates, the
upper limit of kd has been calculated using the equation kd = −ln(0.95)/td,
where td is the time (in seconds) allowed for dissociation. Sensorgrams were
double referenced using the control surface (GST) and blank buffer injec-
tions to subtract baseline drifts from the data sets. To assess reproducibility
of kinetic constants, the analysis was performed in duplicate.
To test whether the interaction between PDE8A1 and Raf-1 is inhibited by
a selective PDE8 inhibitor, MBP–PDE8A1 (100 nM) was preincubated with 50
μM dipyridimole and injected over GST–Raf-1 on the capture surfaces. The
binding mode of dipyridimole and GST Raf-1 was tested separately in
a control experiment.
To generate theMBP–PDE8A1 bacterial expression vector, the Flag–PDE8A1
construct was used as a template to amplify the PDE8A1 insert and incorporate
the SalI and XbaI recognition sites by PCR using the following primers:
Forward primer: 5′-AATCTAGAATGGGCTGTGCCCCGA-3′
Reverse primer: 5′-AAGTCGACCTATTCAGGAGGTGGTC-3′
The PCR product and pMAL–c2x vector (New England BioLabs) were
digested using XbaI and SalI restriction enzymes and ligated. The construct
was sequenced using the following primers:
Forward 1 primer: 5′-GATGAAGCCCTGAAAGACGCGCAG-3′
Reverse 1 primer: 5′-GAT TTA ATC TGT ATC AGG-3′
Forward 2 primer: 5′-GAA GAG TTG TCC GTA ATG-3′
Reverse 2 primer: 5′-GCA GGG ATT GGA CAC ATC-3′
Forward 3 primer: 5′-ATA TCC GAA TGT GTT CAG-3′
Reverse 3 primer: 5′-CAC ATC AGC AGA ATG TGT-3′
To purify Raf-1 and PDE8A1 proteins for the SPR experiments, a 10-mL
overnight culture of BL21 Escherichia coli cells containing the pGEX–GST–
Raf-1 or pMAL–c2x plasmids was added to 500 mL of LB medium and grown
at 37 °C with shaking until the OD600 reached ∼0.6. Expression of the
recombinant fusion proteins was induced by adding 0.1 mM isopropyl-β-D-1-
thiogalactopyranoside. After 4 h cells were pelleted by centrifugation at
7,000 × g for 7 min and were frozen at −80 °C to assist with lysis. The bac-
terial pellet was lysed as described (49), and fusion proteins were isolated by
incubating the lysates with either glutathione Sepharose beads or amylose
resin (Amersham) for 1 h at 4 °C. Beads were washed six to eight times in
PBS, and the fusion proteins were released by incubating with 600 μL of
elution buffer [10 mM glutathione in 50 mM Tris (pH 7.5) or 50 mM maltose]
for 20 min at 4 °C. The elution step was repeated three times, and the
eluates were pooled. Any detergent, glutathione, or maltose was removed
by overnight dialysis using the Slide-A-Lyzer cassettes (Piercenet) in 2 L of
dialysis buffer.
Measuring Cellular Responses with the xCELLigence System. To measure cel-
lular responses with the xCELLigence system, the RTCA SP instrument (Roche
Applied Science) was used according to the supplier’s instructions. The
E-plate 96 (Roche), a single-use, disposable, 96-well microtiter plate with gold
cell-sensor arrays in the bottom that allow the impedance inside each well to
be monitored and assayed in real time, was used to perform cell-based
assays as previously described by G.S.B. (28). The impedance is reported as
arbitrary cell index measurements. HeLa cells were transfected with D/N
PDE8A and 24 h later were seeded onto a 96-well E-plate (Roche) at a den-
sity of 2 × 104 cells per well. Cells were allowed to adhere overnight before
any treatment. For disruptor peptide experiments, cells were treated with
the peptides for 4 h before further treatment. Then, cells were serum
starved for 4 h before treatment with 100 ng/mL EGF. After treatment, the
cell index was measured every 15 s using the xCELLigence system (Roche). To
measure cell death after treatment with 500 nM staurosporine or 10 μM
hydrogen peroxide, HEK293 cells were plated as described above, and the
cell index was measured every 30 min. Cell viability was measured by cal-
culating the cell index of treated cells as a percentage of nontreated cells.
Generation of the PDE8 Deletion in Drosophila. The Drosophila PDE8 deletion
was generated using ﬂippase recombinase and two lines containing ﬂippase
recognition target-bearing piggybac insertions. The piggybac insertions lines
(PDE8d06642 and PDE8f02577) ﬂank most of the PDE8 coding region including
the entire catalytic domain. Individual lines were screened with PCR of ge-
nomic DNA to conﬁrm the loss of the intervening DNA.
Drosophila Survival Assays in Response to Oxidative Stress. Flies of speciﬁed
genotype (5-d-old males and females, housed separately) were starved for 4 h
and then exposed to 20 mM paraquat or 1% H2O2 (both from Sigma) in 1%
sucrose medium in groups of 30, with three biological replicates. Flies were
counted until 100% mortality was reached, and data were expressed as
percent survival ± SEM (n = 3). Data were assessed for signiﬁcance by the
log-rank (Mantel–Cox) test using GraphPadPrism 5.0 software.
Whole-Fly Phospho-ERK Western Blot Analysis. Basal phospho-ERK levels were
analyzed from PDE8-deﬁcient ﬂies compared with two control strains, wild-
type CantonS ﬂies and Exilexis ﬂies, to control for the genetic background
of PDE8-deﬁcient line. Brieﬂy, 50 ﬂies of each genotype were washed and
gently homogenized in ice-cold 3T3 lysis buffer supplemented with 1:100
dilution of protease-inhibitor mixture (Sigma) using an Eppendorf micro-
pestle. The homogenate then was subjected to two successive centrifu-
gations at 1,000 × g at 4 °C for 5 min to remove large cuticle debris and
wings, and the protein concentration was determined using the Bio-Rad
Bradford assay.
Fig. 8. Silencing of PDE8 alters survival responses to oxidative stress in
Drosophila. (A and B) The survival rate of ﬂies fed with 1% hydrogen per-
oxide is reduced signiﬁcantly in (A) male PDE8-deﬁcient ﬂies as compared
with the wild-type CantonS (P = 0.0138) and Exilesis (P < 0.0001) parents (log-
rank Mantel–Cox test) and in (B) female PDE8-deﬁcient ﬂies (P < 0.0001
against both controls). (C and D) The survival rate of (C) male and (D) female
ﬂies fed with 20 mM paraquat is signiﬁcantly reduced in PDE8-deﬁcient ﬂies
as comparedwith both control strains (P< 0.0001; log-rank;Mantel–Cox test).
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